Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT plus pembrolizumab before surgery in early-stage non-small cell lung cancer
2016-003819-36Phase 2Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Immunologic modulation in tumor and immune compartments. Started Apr 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-003819-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003819-36.